Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease

J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):294-6. doi: 10.1097/MPG.0b013e31822938c3.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Child
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Female
  • Humans
  • Infliximab
  • Mycobacterium avium-intracellulare Infection / chemically induced*
  • Mycobacterium avium-intracellulare Infection / complications
  • Mycobacterium avium-intracellulare Infection / diagnosis
  • Opportunistic Infections / chemically induced*
  • Opportunistic Infections / complications
  • Opportunistic Infections / diagnosis
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab